By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel - 25 Worldwide Road Food varieties You Should Attempt
- 3The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- 4Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- 5King Charles shares cancer treatment update, says it's a 'personal blessing'
- How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- Jamie Dimon warns Iran war could drive inflation, interest rates higher
- RSF attack on Sudan’s South Kordofan kills at least 14, including children
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- Millions in JDM Exports and Exotic Supercars Are Currently Trapped at Sea
